Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03103009 · ClinicalTrials.gov registry record · Phase 1
Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03103009 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 1 participants.
The verdict
NCT03103009, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
Interventions
- DRUG Pasireotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03103009
The ClinicalTrials.gov registry entry for NCT03103009 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide is the first listed.
NCT03103009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03103009 about?
NCT03103009 is a clinical study titled "Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia". Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experie...
What is the current status of trial NCT03103009?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-03-22. Estimated completion is 2017-12-22.
What interventions are being tested in trial NCT03103009?
The interventions under investigation include: Pasireotide (DRUG).
Who is sponsoring clinical trial NCT03103009?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.